Drug Profile
Research programme: bacterial infections therapeutics - Viral Genetics
Alternative Names: VGV-SLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Viral Genetics
- Developer VG Life Sciences
- Class Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Sepsis; Staphylococcal infections; Streptococcal infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Sepsis in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Streptococcal-infections in USA